CellEDIT - CRISPR-Edited A549 Cell Line
Let us support you with a custom, high-quality engineered A549 cell line.
We'll handle the CRISPR engineering of your A549 cells, so you focus on your research.
A549 cells are lung carcinoma epithelial cells that are widely used in cancer research and drug discovery. They are the most used human non-small cell lung cancer cell line. These hypotriploid alveolar basal epithelial cells were first derived in 1972 from the cultured pulmonary carcinoma tissue of a 58-year-old Caucasian male.
A549 Cell Line Information
Organism
Human
Tissue Type
Lung
Cell Type
Epithelial
Disease
Carcinoma
Karyotype
Hypotriploid
Donor Information
Age
58
Gender
Male
Ethnicity
Caucasian
A549 Cell Line Applications
Cancer Research: A549 cells are extensively used to study the biology of non-small cell lung cancer, including tumor growth, metastasis, and the molecular mechanisms underlying cancer progression.
Drug Screening & Development: These cells serve as a standard model for testing the efficacy and toxicity of new anticancer drugs, aiding in the identification and optimization of potential therapeutic compounds.
Toxicology Studies: A549 cells are used to assess the cytotoxic effects of various chemicals, environmental pollutants, and potential therapeutic agents, providing insights into their safety and mechanism of action.
Virology Research: Researchers utilize A549 cells to study viral infections, including the mechanisms of viral entry, replication, and host cell response, as well as to develop and test antiviral drugs.
Respiratory Disease Research: These cells are employed to investigate respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, helping to understand disease mechanisms and develop new treatments.
Related Case Studies
Leverage CellEDIT's expertise to boost your research endeavor. With the CellEDIT workflow and within 10 weeks, we can support you with custom and monoclonal knockout A549 cell lines suited for your project needs.
Efficient on
Hard-to-transfect cells
Vector-free
direct intra-nuclear delivery
Minimized Off-Target
Immortalized Cells
Find out how
the CellEDIT workflow enabled the generation of 5 monoclonal HPRT knockout C2C12 cell lines through direct intra-nuclear injection of only 51 cells.
Hard-to-Transfect Cells
Discover how
the CellEDIT workflow facilitated the production of 3 monoclonal HPRT1 knockout SK-MES-1 cell lines, which are notoriously hard-to-transfect.
Available Edits using CellEDIT Engineered Cells
Knockout
Save time in the lab by boosting your research with CellEDIT. Confidently streamline your drug discovery workflow and investigate gene function with effective CRISPR knockouts.
Multiplex Editing
At
CellEDIT, we provide you
with multiplexed cell lines in 10 weeks. The efficiency and gentleness of our vector-free editing through intra-nuclear delivery, makes it an ideal system to perform multiplex gene editing in one go.
Related Resources
Educational
Technical
Introduction to CRISPR Knockout Gene Editing with CellEDIT
An Overview of CellEDIT' CRISPR Cell Line Development Services
CellEDIT' CRISPR Cell Line Development Workflow
CellEDIT's Engineered Cell Lines
CRISPR-Engineered MDA MB 231 Cell Line
CRISPR-Edited Hek293 Cell Line
Media & Downloads
On-Demand CellEDIT's CRISPR Cell Line Engineering Webinar
CellEDIT's Application Note n*1 - Introducing the CellEDIT Workflow
CellEDIT's Application Note n*2 - Overcoming the hard-to-transfect cell line hurdle
Open Access Publication featuring CellEDIT: Antony, Justin S., Anabel Migenda Herranz, Tahereh Mohammadian Gol, Susanne Mailand, Paul Monnier, Jennifer Rottenberger, Alicia Roig‐Merino et al. " Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9" Biotechnology Journal 19, no. 4 (2024): 2300505.